Site-specific reductions of acetylated histone H3 have been measured in clinical samples of prostate cancer in comparison to normal tissue, and in tumor cell lines, in parallel to increased HDAC activity [26]. The gene discussed is HDAC9; the disease is prostate carcinoma.